Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
1995 · Nature Medicine · 538 citations
https://doi.org/10.1038/nm0895-792
N
Nancy E. Kohl
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
222
Papers
12.4K
Citations
52
h-index
98
i10-index
Nancy E. Kohl is an academic researcher from RheinMain University of Applied Sciences. The author has contributed to research in topics: Cancer-related Molecular Pathways & Protein Kinase Regulation and GTPase Signaling & Liver physiology and pathology. The author has an h-index of 52, co-authored 189 publications.
ORCID: 0000-0003-4028-1866Papers by this author
worksProtein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.
1994 · Proceedings of the National Academy of Sciences · 286 citations
https://doi.org/10.1073/pnas.91.19.9141
Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo.
1993 · Journal of Biological Chemistry · 258 citations
https://doi.org/10.1016/s0021-9258(18)52998-7
Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
1999 · PubMed · 68 citations
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
2024 · Cancer Discovery · 43 citations
https://doi.org/10.1158/2159-8290.cd-24-0231
Supplementary Figures S1-S17 from NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
2024 · 0 citations
https://doi.org/10.1158/2159-8290.27938939
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat